Posters presented at the 2023 American Thoracic Society International Conference called for improvements in care for chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.
Addition of ravulizumab to BSC did not improve survival or other secondary outcomes.
Safety findings were consistent with the known safety profile of ravulizumab in its
approved indications. Despite the lack of efficacy, the study adds value for future
research into complement therapeutics in critical illnesses by showing that C5 inhibition
can be accomplished in severely ill patients.
News Scan for Nov 04, 2022 umn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umn.edu Daily Mail and Mail on Sunday newspapers.
A recent study conducted on the residents of Amsterdam, the Netherlands, describes that people with mild COVID-19 experience better health-related quality of life after one year of disease onset than those with moderate or severe COVID-19.